Vivos Therapeutics (VVOS) Cash & Equivalents (2019 - 2026)

Vivos Therapeutics (VVOS) has 8 years of Cash & Equivalents data on file, last reported at $2.1 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $2.1 million, down 10.33% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.1 million (down 10.33% YoY), and the FY2025 annual result was $2.0 million, down 67.59% from the prior year.
• Cash & Equivalents rose to $2.1 million in Q1 2026 per VVOS's latest filing, from $2.0 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $17.8 million in Q1 2022 and troughed at $1.0 million in Q3 2023.
• A 5-year average of $5.3 million and a median of $3.9 million in 2023 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2024: Cash & Equivalents sank 85.34% in 2022, then jumped 531.1% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $3.5 million in 2022, then sank by 53.31% to $1.6 million in 2023, then surged by 281.01% to $6.3 million in 2024, then slumped by 67.59% to $2.0 million in 2025, then increased by 3.5% to $2.1 million in 2026.
• Business Quant data shows VVOS's Cash & Equivalents at $2.1 million in Q1 2026, $2.0 million in Q4 2025, and $3.1 million in Q3 2025.